ArticleCardiovascular diabetology2015
Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.
Article in Cardiovascular diabetology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study.Cardiovascular diabetology · 2022Trial
- Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.Cardiovascular diabetology · 2016Trial
- Hypoglycaemic stimulation of macrophage cytokine release is suppressed by AMP-activated protein kinase activation.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Safety and effectiveness of apixaban use for stroke prevention during Ramadan fasting (the API-RAM study).Frontiers in pharmacology · 2025Article
- The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk.International journal of molecular sciences · 2023Review
- Effects of Hypoglycemia on Cardiovascular Function in Patients with Diabetes.International journal of molecular sciences · 2023Review
- The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance.Journal of clinical laboratory analysis · 2022Article
- DNase 1 Protects From Increased Thrombin Generation and Venous Thrombosis During Aging: Cross-Sectional Study in Mice and Humans.Journal of the American Heart Association · 2022Article
- Association of glycated hemoglobin ACardiovascular diabetology · 2021Article
- Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation.Cardiovascular diabetology · 2021Review
- Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell-free DNA.Research and practice in thrombosis and haemostasis · 2021Article
- Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation.Cardiovascular diabetology · 2018Article
- Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.Journal of thrombosis and thrombolysis · 2018Article
- Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.Heart failure reviews · 2018Review
- Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease.Cardiovascular diabetology · 2018Article
- Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.Cardiovascular diabetology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of low blood glucose on thrombin generation and fibrin clot properties in type 2 diabetes (T2DM).
methodsIn 165 patients with T2DM and high cardiovascular risk, we measured ex vivo plasma fibrin clot permeation [Ks], turbidity and efficiency of fibrinolysis including clot lysis time [t50%], together with thrombin generation and platelet activation markers in relation to fasting blood glucose.
resultsAs compared to patients in medium (4.5-6.0 mmol/l, n = 52) and higher (>6.0 mmol/l, n = 75) glucose group, subjects with low glycemia (<4.5 mmol/l, n = 38) had lower Ks by 11% (p < 0.001) and 8% (p = 0.01), respectively, prolonged t50% by 10% (p < 0.001) and 7% (p = 0.016), respectively, and higher peak thrombin generation by 21% and 16%, respectively (p < 0.001 for both). There were no significant differences in Ks and t50% between patients in medium and higher glucose group. In the whole group, a J-shape relationship was observed between glycemia and the following factors: peak thrombin generation, Ks and t50%. Only in patients with HbA1c < 6.0% (42 mmol/mol) (n = 26) fasting glucose positively correlated with Ks (r = 0.53, P = 0.006) and inversely with t50% (r = -0.46, P = 0.02). By multiple regression analysis, after adjustment for age, fibrinogen, HbA1c, insulin treatment and T2DM duration, fasting glycemia was the independent predictor of Ks (F = 6.6, df = 2, P = 0.002), t50% (F = 8.0, df = 2, P < 0.001) and peak thrombin generation (F = 13.5, df = 2, P < 0.0001).
conclusionsIn T2DM patients fasting glycemia <4.5 mmol/l is associated with enhanced thrombin formation and formation of denser fibrin clots displaying lower lysability, especially when strict glycemia control was achieved (HbA1c<6.0%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.